July 8, 2016
Written by Lisa Rossi, Director of Communications & External Relations, Microbicide Trials Network
Women need HIV prevention products that are safe and effective to use in all stages of their lives, including during pregnancy and breastfeeding, when they may be most susceptible to infection. While the new WHO guidelines indicate that PrEP can be used during pregnancy, South Africa’s guidelines caution that not enough is known at this time about PrEP’s risks and benefits for HIV-uninfected women and their babies. What about new products, such as the dapivirine vaginal ring, or long-acting injectables? At which point and in which settings should questions about safety in this population be addressed?
This satellite session is on Monday 18 July at 14:45 – 16:45. More information about this session >>